A safety warning should neither be minimized nor expanded beyond what it says. The FDA's compounding-risk page identifies concerns about ipamorelin acetate, including possible immune reactions related to aggregation or peptide impurities. It also notes serious events, including death, reported in an intravenous gastric-motility study and insufficient safety information for certain other injectable routes.
Those statements are not equivalent to saying that ipamorelin caused every reported event. They are also not a basis for declaring another route safe.
Reporting and causation are different
An adverse event is something that happened during observation. Determining whether an intervention caused it requires examination of timing, competing explanations, comparison groups and biological plausibility. In postoperative research, underlying illness and surgery are important parts of that assessment.
The published postoperative trial abstract should therefore be read together with, not substituted for, detailed safety review. A general tolerability statement cannot answer every causal question about individual serious events.
The route gap is especially important. It is tempting to reason that an event reported with intravenous exposure is irrelevant to another route. That conclusion requires evidence, not assumption. Absorption patterns and product characteristics may differ; the absence of adequate information is precisely what prevents a confident safety comparison.
Immune-risk concerns are also distinct from the intended hormonal action. A product can have the expected active ingredient while still requiring assessment of impurities, aggregates and formulation. Purity, sterility and clinical tolerability are separate questions.
For a reader, the useful conclusion is neither panic nor reassurance. The warning identifies unresolved safety issues that deserve qualified evaluation. It does not provide a personal risk estimate or an alternative administration strategy. Anyone discussing a prescribed or compounded treatment should bring the exact product information and warning to their licensed clinician or pharmacist; an online summary cannot replace that assessment.